Thanks for the interesting post Marghanita. Here’s an in-depth summary of the Bahrain study:
“The percentage of deaths among all PCR positive post-vaccination COVID-19 cases among recipients of Sinopharm was 0.46% (i.e, 112 deaths) versus 0.15% for Pfizer/BioNtech (i.e., 3 deaths) and 0.03% for AZ / Covishield (1 death). This trend was consistent for all COVID-19 events. (Table 1 Page 10).” ABSTRACT Summary Here we present an analysis of COVID-19 related outcomes from Bahrain, a country with a total population of 1.501 million, where four vaccines were deployed (total vaccinated =1,003,960), including Astra-Zeneca (AZ / Covishield), Pfizer / BioNtech, Sinopharm and Sputnik V. Between December 2020 and July 2021, there were 569,054 individuals vaccinated with Sinopharm, and 184,526 with Sputnik, and 73,765 with AstraZeneca (AZ / Covishield) and 169,058 with Pfizer/BioNtech vaccines, while 245,876 were used as the unvaccinated case-control cohort (Fig 1 Page 10). These unvaccinated included travellers and individuals undergoing random tests in areas of high population density. COVID-19 Outcomes There were a total of 180,840 PCR positive COVID-19 cases identified among all individuals, with 134,728 among those 18 years and older. There were 13,105 hospitalizations, including 1,636 ICU admissions, and a total of 1,030 deaths. We assessed COVID-19 hospitalizations, ICU admissions and deaths by vaccination status. We further examined the data by age, for those >50 versus < 50 years of age, taking into account the known increase in risk of COVID-19 related morbidity and mortality among those >50 years of age. In order to limit multiple comparisons, we did paired testing among these groups: Unvaccinated vs Sinopharm, Unvaccinated vs Pfizer/BioNtech, Unvaccinated vs AZ / Covishield, and Unvaccinated vs Sputnik V. Research Findings Using pairwise comparisons between unvaccinated individuals (> 50 and <50 years), we found significantly higher % of hospitalization, ICU admissions and deaths in the unvaccinated group compared to the vaccinated group for all four vaccines (Table 1 Page 10). The percent of deaths among all COVID-19 cases in unvaccinated people >50 years of age was 3.8-fold higher compared to the Sinopharm, and approximately 7.5-fold higher than the Sputnik V vaccine recipients. There were no deaths reported in the AZ / Covishield vaccinated group. In patients <50 years, the percent of death among all COVID-19 cases in unvaccinated people were 8.1-fold higher compared to Sinopharm vaccine recipients. There were no deaths reported in this age cohort in Sputnik V and Pfizer/BioNtech vaccine recipients, and 1 death among the AZ / Covishield vaccine recipients (Table 1 Page 10). The percentage of deaths among all PCR positive post-vaccination COVID-19 cases among recipients of the Sinopharm vaccine was 0.46% (i.e, 112 deaths) versus 0.15% for Pfizer/BioNtech (i.e., 3 deaths) and 0.03% for AZ / Covishield (1 death). This trend was consistent for all COVID-19 events, i.e., infection, hospitalization, ICU admission and death. (Table 1 Page 10). The study: https://assets.researchsquare.com/files/rs-828021/v1_covered.pdf?c=1629920029 _______________________________________________ Link mailing list [email protected] https://mailman.anu.edu.au/mailman/listinfo/link
